INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $70,061 | -10.2% | 1,345 | +9.2% | 0.00% | -33.3% |
| Q2 2023 | $78,010 | +16.9% | 1,232 | 0.0% | 0.00% | +50.0% |
| Q1 2023 | $66,713 | -49.7% | 1,232 | -50.8% | 0.00% | -66.7% |
| Q4 2022 | $132,512 | +13.3% | 2,504 | -0.1% | 0.01% | +20.0% |
| Q3 2022 | $117,000 | -18.2% | 2,507 | +0.1% | 0.01% | -28.6% |
| Q2 2022 | $143,000 | -5.9% | 2,504 | -0.9% | 0.01% | +16.7% |
| Q1 2022 | $152,000 | +10.1% | 2,526 | -4.5% | 0.01% | +20.0% |
| Q4 2021 | $138,000 | +39.4% | 2,644 | -0.2% | 0.01% | +25.0% |
| Q3 2021 | $99,000 | -2.9% | 2,650 | +6.0% | 0.00% | 0.0% |
| Q2 2021 | $102,000 | +20.0% | 2,500 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $85,000 | +6.2% | 2,500 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $80,000 | +25.0% | 2,500 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $64,000 | – | 2,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |